Nocion Therapeutics raised $62M in a Series B financing led by Arkin Bio Capital and Monograph Capital to advance the lead program in Cough into later stage development.

Mar 04, 2024•over 1 year ago

Amount Raised

$62 Million

Round Type

series b

WalthamBiotechnology

Investors

Osage University PartnersMission Bio CapitalMass General Brigham VenturesF Prime CapitalCanaan PartnersMonograph CapitalArkin Bio Capital

Description

Nocion Therapeutics announced a $62 million Series B funding round to advance its lead program in Cough into later stage development. The proceeds from the financing will be used to evaluate the lead program, Taplucanium Dry Powder for Inhalation, in a Phase 2b study in Chronic Cough patients.

Company Information

Company

Nocion Therapeutics

Location

Waltham, Massachusetts, United States

About

Nocion Therapeutics is a biopharmaceutical company developing novel treatments for silencing neurons. The company’s platform of unique molecular entities selectively affects inflamed nociceptors. Treatment using this approach aims to provide more durable and robust local analgesic effects while minimizing numbness or paralysis and other systemic off-target effects. The company’s mission is to safely alleviate suffering for millions of patients with conditions arising from activated sensory neurons including chronic cough, pain and itch.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends